832-497-2220 [email protected]

Rehabilitation Devices

Driven by the following and other factors, the medical rehabilitation industry in China is rapidly expanding.  

– Accelerating population aging

– The continuous and steady growth of medical insurance funds

– Increase in the population of chronic disease

– Policy and financial support in disability rehabilitation

– Hierarchical diagnosis and treatment promote the development of primary medical institutions

According to KPMG’s report, in 2018, the total consumption of China’s rehabilitation medical market was RMB¥ 58.3 billion (approximately USD$ 8.3 billion). The compound growth rate is 26.9% from 2011 to 2018. It is estimated that the scale of the rehabilitation medical service market will reach RMB¥ 103.2 billion (approximately USD$ 14.7 billion) in 2021.

Submitted Projects:

Project ID: REH101

Category: Rehabilitation Devices/Drugs

Keyword: Insulin drugs

Project/Product Summary:

Project REH101 employs its proprietary excipient library, BioXxxx®, to unlock new clinical benefits of already-approved treatments in the fields of diabetes and metabolism

Indications: Diabetes and other metabolic diseases

Stage: Clinical Phase III

Partnering Objectives: Joint development, Commercial license

Country: France

Project ID: REH102

Category: Rehabilitation Devices/Drugs

Keyword: Artificial Intelligence Remote Treatment for Heart Failure

Project/Product Summary:

Project REH101 is committed to solving the huge clinical problem of heart failure rehospitalization. The company uses remote monitoring and AI algorithms to provide doctors and patients with the best diagnostic basis and medication control, effectively reducing the risk of heart failure patients with relapse and greatly reducing the frequency of hospitalization.

Indications: Cardiovascular diseases

Stage: Technology platform

Partnering Objectives: Fundraising, business cooperation

Country: France

Project ID: REH104

Category: Rehabilitation Devices/Drugs

Keyword: Protease activator

Project/Product Summary:

Project REH104 develops innovative treatments for metabolic disorders, including type 2 diabetes and NASH. With our partner Sumitomo Dainippon Pharma, we are conducting a Phase 3 program for Imeglimin for type 2 diabetes in Japan. Roivant Sciences is responsible for Imeglimin’s development and commercialization outside of Sumitomo Dainippon Pharma’s territories, including the US and Europe. PXL770, a direct adenosine monophosphate-activated protein kinase activator, is in Phase 2a for NASH and has the potential to treat additional metabolic diseases. PXL065, a mitochondrial pyruvate carrier inhibitor, is in Phase 1 for NASH. Poxel also has earlier-stage programs for metabolic, specialty and rare diseases.”

Indications: Type 2 diabetes, NASH non-alcoholic fatty liver

Stage: Phase III

Partnering Objectives: Lisencing

Country: France

Potential Chinese Partners: